• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Authors » Daniel Carlat, MD

Articles by Daniel Carlat, MD

Switching Antidepressants: Direct Switch vs. Cross Taper (Med Fact Book Mini-Series, Part 2)

November 4, 2025
Daniel Carlat, MD

Switching antidepressants isn’t hard.

Unless you rush it—or forget the exceptions.

Part 2: Med Fact Book Mini-Series




Read More
Fact Sheet

Omega-3 Fatty Acids (Fish Oil) Fact Sheet for General Psychiatry

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Omega-3 fatty acids form the lipid bilayers of cell membranes, and supplementing our natural dietary supply may have psychological and cardiological benefits.




Read More
Fact Sheet

Lithium (Eskalith, Lithobid) Fact Sheet for General Psychiatry

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Lithium is the gold standard for bipolar disorder.




Read More
Fact Sheet

Lamotrigine (Lamictal, Lamictal XR, Subvenite) Fact Sheet

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Lamotrigine is a good choice for maintenance treatment of bipolar disorder, especially to prevent depressive episodes.




Read More
Fact Sheet

Carbamazepine (Epitol, Equetro, Tegretol, others) Fact Sheet

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Equetro is the only FDA-approved formulation of carbamazepine for bipolar disorder, but use of other formulations would result in the same effects at a lower price.




Read More
Fact Sheet

Propranolol (Inderal) Fact Sheet

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Propranolol has several uses in psychiatry, including performance anxiety, drug-induced tremor, and akathisia.




Read More
Fact Sheet

Prazosin (Minipress) Fact Sheet for General Psychiatry

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Prazosin is an alpha-1 antagonist (FDA approved for hypertension) that has become popular as a treatment for insomnia/nightmares associated with post-traumatic stress disorder (PTSD). 




Read More
Fact Sheet

N-Acetylcysteine (NAC) Fact Sheet for General Psychiatry

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

NAC is a glutamate modulator derived from the amino acid cysteine. It’s been tested in many psychiatric conditions, but shows the most promise as an adjunctive treatment to selective serotonin reuptake inhibitors for compulsive behaviors like obsessive-compulsive disorder (OCD), trichotillomania, nail biting, and skin picking.




Read More
Fact Sheet

Lorazepam (Ativan, Loreev XR) Fact Sheet for General Psychiatry

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

When a benzodiazepine is appropriate for use (short term; minimal risk of abuse), we consider lorazepam to be a first-line agent.




Read More
Fact Sheet

Lavender Essential Oil (CalmAid, Silexan) Fact Sheet for General Psychiatry

November 3, 2025
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Lavender essential oil (Silexan) is a well-tolerated, over-the-counter option for mild to moderate generalized anxiety disorder (GAD), supported by studies showing effect sizes comparable to standard treatments.




Read More
Previous 1 2 3 4 5 6 7 8 9 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • PB5e_3DCover.png

    Psychiatry Practice Boosters, Fifth Edition (2026)

    This fifth edition teaches you the key points of 66 of the most clinically relevant studies in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2697712297.jpg
    General Psychiatry

    How to Explain TMS

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.